Danila, D. C., Waterhouse, D. M., Appleman, L. J., Pook, D. W., Matsubara, N., Dorff, T. B., … Kelly, W. K. (2022). A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Danila, Daniel Costin, David Michael Waterhouse, Leonard Joseph Appleman, David William Pook, Nobuaki Matsubara, Tanya B. Dorff, Jae-Lyun Lee, et al. “A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Danila DC, Waterhouse DM, Appleman LJ, Pook DW, Matsubara N, Dorff TB, et al. A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Danila, Daniel Costin, et al. “A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Danila DC, Waterhouse DM, Appleman LJ, Pook DW, Matsubara N, Dorff TB, Lee J-L, Armstrong AJ, Kim M, Horvath L, Sumey CJ, Cooner F, Salvati M, Stieglmaier J, Kelly WK. A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY. 2022.